Beranda › Limfoma Sel B Besar Difus › Texas › Houston
Uji klinis Limfoma Sel B Besar Difus di Houston, TX
17 studi untuk Limfoma Sel B Besar Difus mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Menerima pesertaFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Menerima pesertaFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Menerima pesertaFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Menerima pesertaFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Menerima pesertaFase 1
- Md Anderson Cancer Center, Houston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Menerima pesertaFase 2
- MD Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Menerima pesertaFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Menerima pesertaFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Menerima pesertaFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Menerima pesertaFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Menerima pesertaFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Menerima pesertaFase 1
- MD Anderson Cancer Center, Houston
Uji klinis Limfoma Sel B Besar Difus di kota lain
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Los Angeles, CA17 studi
- Boston, MA16 studi
- Milwaukee, WI16 studi
- Philadelphia, PA15 studi
- Portland, OR15 studi
- Durham, NC14 studi
- Nashville, TN14 studi
- Dallas, TX13 studi
- Salt Lake City, UT12 studi
Studi lain di Houston
- Kanker Paru Non-Sel Kecil145 studi
- Kanker Payudara126 studi
- Kanker (semua jenis)121 studi
- Kanker Metastatik104 studi
- Kanker Kolorektal102 studi
- Kanker Ovarium90 studi
- Leukemia Mieloid Akut85 studi
- Kanker Paru78 studi
- Kanker Prostat76 studi
- Kanker Endometrium68 studi
- Kanker Pankreas62 studi
- Melanoma59 studi
Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.